These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges. Harvey PR; Gordon C BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653 [TBL] [Abstract][Full Text] [Related]
4. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Reddy V; Jayne D; Close D; Isenberg D Arthritis Res Ther; 2013; 15 Suppl 1(Suppl 1):S2. PubMed ID: 23566295 [TBL] [Abstract][Full Text] [Related]
5. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases]. Tanaka Y Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410 [TBL] [Abstract][Full Text] [Related]
6. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. Iwata S; Saito K; Tokunaga M; Yamaoka K; Nawata M; Yukawa S; Hanami K; Fukuyo S; Miyagawa I; Kubo S; Tanaka Y J Rheumatol; 2011 Apr; 38(4):633-41. PubMed ID: 21159836 [TBL] [Abstract][Full Text] [Related]
7. B-cell-targeted therapy for systemic lupus erythematosus: an update. Ding C; Foote S; Jones G BioDrugs; 2008; 22(4):239-49. PubMed ID: 18611066 [TBL] [Abstract][Full Text] [Related]
8. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date. Marks SD; Tullus K Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407 [TBL] [Abstract][Full Text] [Related]
9. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. Nakayamada S; Iwata S; Tanaka Y Int J Rheum Dis; 2015 Feb; 18(2):208-18. PubMed ID: 25557245 [TBL] [Abstract][Full Text] [Related]
10. SLE - Rituximab in lupus. Eisenberg R Arthritis Res Ther; 2003; 5(4):157-9. PubMed ID: 12823844 [TBL] [Abstract][Full Text] [Related]
11. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Eisenberg R Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580 [TBL] [Abstract][Full Text] [Related]
12. Rituximab in systemic lupus erythematosus and lupus nephritis. Beckwith H; Lightstone L Nephron Clin Pract; 2014; 128(3-4):250-4. PubMed ID: 25471633 [TBL] [Abstract][Full Text] [Related]
13. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases. Tanaka Y Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614 [No Abstract] [Full Text] [Related]